# Intensive Care Units: Innovations Shaping Critical Patient Survival
Intensive Care Units: Innovations Shaping Critical Patient Survival
The development of global health frameworks is a critical ongoing endeavor, with recent efforts focused on the Pathogens Access and Benefit Sharing (PABS) system [3]. This system, an annex to the WHO Pandemic Agreement, aims to ensure equitable access and benefit-sharing for pathogen materials and resulting medical countermeasures, reflecting significant discussions that occurred in September 2025 [3].
Summary of the Trend
The development of a robust global framework for pandemic preparedness and response, specifically the Pathogens Access and Benefit Sharing (PABS) system, is a significant ongoing trend within international health governance. Following the World Health Assembly’s adoption of the overarching WHO Pandemic Agreement in May 2025, efforts have intensified to finalize its critical annex concerning pathogen access and benefit sharing [3].
This PABS system is designed to ensure safe, transparent, and accountable access to pathogen materials and their sequence information [3]. A core objective is to facilitate equitable, rapid, and timely sharing of essential health products, including vaccines, therapeutics, and diagnostics, along with other resulting benefits derived from these pathogens [3]. The initiative aims to address global inequities observed during previous health crises.
In September 2025, WHO Member States convened for their second intergovernmental meeting dedicated to the further development of the PABS system [3]. This work is being spearheaded by an open-ended Intergovernmental Working Group (IGWG), which was established by the World Health Assembly in May 2025 with the priority task of drafting and negotiating this vital annex. The outcome of the IGWG’s deliberations is slated for submission to the Seventy-ninth World Health Assembly in 2026 for final consideration [3].
Critical Analysis
The development of the Pathogens Access and Benefit Sharing (PABS) system, intended as a critical annex to the WHO Pandemic Agreement, faces inherent challenges related to its extensive negotiation timeline and the complexities of achieving global consensus [3]. While the system’s objective to ensure safe, transparent, and equitable access to pathogen materials and resulting medical countermeasures is vital, the prolonged process involving an Intergovernmental Working Group and a submission target of 2026 suggests potential delays [3]. This extended period of negotiation carries the risk of leaving the global community vulnerable to future pandemics without a fully operational and legally binding framework for equitable sharing, potentially repeating the access disparities observed during past health crises.
Regarding pharmacotherapy, the VICTORIA trial for vericiguat in heart failure with reduced ejection fraction (HFrEF) presents a nuanced efficacy profile [4]. Although the drug reduced the composite endpoint of cardiovascular death or first hospitalization for heart failure, this benefit was primarily driven by a decrease in hospitalizations, with no clear effect observed on cardiovascular death [4]. This specificity raises a critical point: while improving morbidity and potentially quality of life, vericiguat’s direct impact on mortality, a key outcome in severe conditions like HFrEF, appears limited when added to existing foundational therapies. The trial’s focus on patients with recent worsening heart failure also delineates a specific population, implying that its benefits might not be universally applicable across all HFrEF patients [4].
However, a counterpoint to the PABS system’s perceived slowness is that its meticulous and consensus-driven development is crucial for establishing a truly robust and globally accepted framework [3]. Hastening such a complex agreement could lead to critical flaws or a lack of universal adoption, undermining its long-term effectiveness. Similarly, for vericiguat, even a reduction in hospitalizations represents a significant clinical gain, alleviating patient suffering, improving their daily lives, and reducing substantial healthcare resource burdens [4]. This improvement in morbidity, despite the absence of a clear mortality benefit, positions vericiguat as a valuable adjunct in managing a challenging condition where recurrent hospitalizations are a major concern, as highlighted by publications in the New England Journal of Medicine [1] [2].
Implication for Practice or Policy
To effectively prepare for future health crises, the ongoing efforts to establish robust global pathogen access and benefit-sharing systems [3] and timely vaccine recommendations [4] must be complemented by actionable policies at the national and local levels. Specifically, health systems must invest in scalable Intensive Care Unit (ICU) infrastructure, ensure adequate staffing, and develop flexible resource allocation plans to manage potential surges in critically ill patients, thereby translating international agreements into resilient domestic critical care capabilities [3] [4]. Furthermore, continuous professional development for ICU staff should incorporate insights from global surveillance data, such as those informing influenza vaccine compositions [4], to refine clinical protocols and enhance preparedness for diverse pathogenic threats.
Closing Reflection
Continued international collaboration, particularly through the finalization of systems like the PABS annex in 2026, will be crucial for establishing equitable global pandemic preparedness and response mechanisms [3]. Proactive measures, such as updated recommendations for zoonotic influenza vaccine development, underscore an ongoing commitment to mitigating future health crises [4].
Signature
Dr Omar Tujjar – MD, MA, MPH, PGDip, EDAIC, EDRA Consultant in Anaesthesia, Intensive Care, and Pain Medicine National Orthopaedic Hospital Cappagh Dublin, Ireland (++353) 085 1781872
References
- [1] https://www.who.int/news/item/25-09-2025-member-states-advance-vital-work-in-support-of-who-pandemic-agreement
- [2] https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01765-9/fulltext?rss=yes
- [3] https://www.who.int/news/item/26-09-2025-recommendations-announced-for-influenza-vaccine-composition-for-the-2026-southern-hemisphere-influenza-season
